echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > The United States will cooperate with the United Kingdom to speed up the development of new antibiotics

    The United States will cooperate with the United Kingdom to speed up the development of new antibiotics

    • Last Update: 2016-08-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: nai500 2016-07-29 the United States and the United Kingdom reached a new project to accelerate the development of new antibiotics, with a budget of hundreds of millions of dollars, aimed at solving the increasingly serious drug resistance problem The new partnership, called the anti antibiotic bacterial biomedical accelerator (carb-x), brings together government, academic and pharmaceutical industries to accelerate the development of new drugs and diagnostic methods The U.S Department of health and human services said Thursday it will provide $30 million in the first year and a total of $250 million over five years The UK centre for antimicrobial resistance will invest $14 million initially and $100 million over a five-year period In addition, the Wellcome Trust in London will also provide a fund of undisclosed amount The birth of carb-x originated from the cause of antibiotic resistant bacteria proposed by US President Barack Obama in 2015, as well as the investigation of antibiotic resistance launched by former Goldman Sachs economist Jim O'Neill for the British government in the world Jim O'Neill's final report, released in May this year, concluded that countries around the world need to work together to add new antibiotics and reduce the unnecessary use of existing antibiotics "Drug resistant bacterial infections have killed people all over the world," said Jeremy Farrar, head of Wellcome Trust "To solve this level of problem, we can only work together globally to curb the massive abuse of existing antibiotics and accelerate the development of new antibiotics." Carb-x will be headquartered at Boston University School of law, led by renowned health law researcher Kevin outerson.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.